Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 561 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Nonalcoholic Fatty Liver Clear all

Conditions: Nonalcoholic Fatty Liver Disease, Physician
Interventions: Interview, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, Obesity
Interventions: Mindfulness Based Stress Reduction (MBSR); Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: BIO89-100, Placebo; Drug
Lead sponsor: 89bio, Inc.; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 88
States / cities: Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 68 more

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: Fish Oil Supplementation, Placebo Supplementation; Drug
Lead sponsor: Columbia University; Other
Eligibility: 12 Years to 18 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: NAFLD, NASH
Interventions: LiverFASt; Diagnostic Test
Lead sponsor: Fibronostics USA, Inc; Other
Eligibility: 18 Years to 80 Years
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Non-alcoholic Fatty Liver Disease, Diabetes
Interventions: Dietary intervention (calorie restricted diet); Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 60 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Vallejo, California

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: GSK4532990; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 14
States / cities: Chula Vista, California • Montclair, California • San Diego, California + 8 more

Conditions: Non-alcoholic Fatty Liver Disease, Liver Cirrhosis
Interventions: CC-90001, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 64
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 48 more

Conditions: NASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver Disease
Interventions: Bariatric surgery, HepQuant SHUNT Dual Cholate Liver Diagnostic Kit; Procedure · Device
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Obesity, Weight Loss, Body Weight, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, NAFLD
Interventions: Embospheres Microspheres; Device
Lead sponsor: Keith Pereira, MD:; Other
Eligibility: 22 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Nonalcoholic Steatohepatitis, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease
Interventions: Cenicriviroc; Drug
Lead sponsor: Tobira Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 41
States / cities: Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more

Conditions: Hepatic Encephalopathy, Cirrhosis, Nonalcoholic Steatohepatitis, Hepatitis C
Interventions: Not listed
Lead sponsor: OSF Healthcare System; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: Sigmoidoscopy; Procedure
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 35 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH)
Interventions: Miricorilant, Fluvoxamine; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Obesity, Morbid, NASH - Nonalcoholic Steatohepatitis, Chronic Inflammation
Interventions: Bariatric surgery; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Interventions: Pegozafermin, Placebo; Biological · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 154
States / cities: Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 132 more

Conditions: Non-Alcoholic Steatohepatitis
Interventions: EDP-305 Dose 1, EDP-305 Dose 2, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 70
States / cities: Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 56 more

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: San Diego, California

Conditions: Non-alcoholic Steatohepatitis (NASH)
Interventions: No Intervention; Procedure
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 5,311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 30
States / cities: Coronado, California • Gardena, California • La Jolla, California + 20 more

Conditions: Non-Alcoholic Steatohepatitis
Interventions: SHP626, Placebo; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Fatty Liver
Interventions: Weight Management (diet, exercise, and behavior modification); Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: NGM282, Placebo; Biological · Other
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 36
States / cities: Chandler, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 28 more

Conditions: Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis With Liver Fibrosis
Interventions: Placebo, PF-06865571, PF-05221304; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 184
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 101 more

Conditions: HIV Infections, Coronary Artery Disease, Non-Alcoholic Fatty Liver Disease
Interventions: Not listed
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

Patient and Physician Perspectives on Non-Alcoholic Fatty Liver Disease

Effects of Mindfulness Based Stress Reduction Intervention in Patients With Non-alcoholic Fatty Liver Disease

Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)

Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study

Validation of the LiverFASt Test and the Associated Fibrosis Staging Scores Compared to Liver Tissue Pathology Via Liver Biopsy

De Novo Lipogenesis, Lipid and Carbohydrate Metabolism in Non-alcoholic Fatty Liver Disease

Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH

Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Biomarkers of Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis Following Bariatric Surgery

Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis

Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome

Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver Disease

Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis

Development of Kinetic Biomarkers of Liver Fibrosis Measuring NAFLD

Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)

Safety and Tolerability Study of SHP626 in Overweight and Obese Adults

Weight Management in Nonalcoholic Steatohepatitis

Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons